Loading clinical trials...

COMPLETED

Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple Sclerosis

Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple Sclerosis: Sub-study Within the Swiss Multiple Sclerosis Cohort (SMSC)

NCT03632473•University Hospital, Basel, Switzerland

View on ClinicalTrials.gov

Summary

Utility of Multimodal Evoked potentials (mmEP) for monitoring disease course and prediction of progression at different stages of Multiple Sclerosis (MS) is investigated

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•diagnosed with a clinically isolated syndrome (CIS) or MS with a relapsing-remitting (RRMS) or a primary progressive disease course (PPMS):
•CIS: EDSS \<= 5.5 within six months of first clinical event
•early RRMS: EDSS: \<= 3.5 disease course of 5 up to 10 years
•late RRMS: EDSS: 2.0-5.5 inclusive disease course of 5 to 15 years
•PPMS: EDSS: 2.0-6.5 inclusive disease course up to 15 years
•participation in the Swiss Multiple Sclerosis Cohort Study (SMSC)
•mental ability to cooperate
•written informed consent

Exclusion Criteria

•alcohol or substance abuse
•progressive disease other than Multiple Sclerosis
•psychiatric disorder requiring a treatment by a psychiatrist
•patients with movable metal implants, e.g. pace-maker, stents, deep brain stimulators etc.;(patients with jaw- or bone-fixed metal implants can be included)

Locations (3)

Dep. of Neurology, Hospital of the University of Basel

Basel, Switzerland

Hopitaux universitaires de Genève

Geneva, Switzerland

Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano

Lugano, Switzerland

Key Dates

Start Date

August 28, 2014

Primary Completion Date

June 26, 2020

Completion Date

June 26, 2020

Last Updated

September 19, 2024

Enrollment

ACTUAL participants

Conditions

Multiple Sclerosis

Interventions

multimodal evoked potentials (mmEP)

DIAGNOSTIC_TEST

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634

Multiple SclerosisMultiple Sclerosis-Relapsing-Remitting+1 more

View study

RECRUITINGPHASE3

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504

Secondary Progressive Multiple Sclerosis (SPMS)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 19, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple Sclerosis

Inclusion Criteria

Exclusion Criteria

Intermittent Hypoxia in Persons With Multiple Sclerosis

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study